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Summary The volume doubling time (T2) of 52 lung metastases in 21 patients was calculated from
measurements done on plain chest radiographs. Follow-up times ranged from 14 to 819 days.
The measurements were fairly well reproducible in the majority ofpatients, although considerable discrepan-
cies in T2 estimates made by two independent observers were found in a few patients.
The median doubling time was 34.9 days (estimated 95% range 3.9 to 352 days). The variation of T2:s
between patients was significantly (P = 0.0001) larger than that between T2: ofmultiple metastases in the same
patients. The growth of the metastases seemed to be well described by a simple exponential function in all
patients with more than two measurements, without evidence of Gompertzian growth.
There seemed to be a linear correlation between the logarithm of T2 and log-survival time from diagnosis of
metastatic disease, even if only one third of the variation of survival times between patients could be explained
by differences in T2. T2 was not a significant factor for survival in Cox-analysis (P = 0.10).
Measurement of the growth rate of lung metastases from
both sarcomas and non-sarcomatous malignancies has for
more than three decades been one of the most important
sources of information on the growth characteristics of
human malignancies. Sarcomas are especially well suited for
this kind of studies due to their propensity for lung metas-
tases and the often well circumscribed easily measurable
lesions. Tumour doubling time measured from chest x-rays
has been shown to be an important prognostic factor for
overall survival in both primary and secondary lung tumours
(Joseph et al., 1971; Mattson & Holsti, 1980; Spratt &
Spratt, 1964). In recent years the development of novel
methods for the study of tumour proliferation by flow
cytometry and immunohistochemistry have stimulated a
renewed interest in the measurement ofgrowth characteristics
of human tumours. The most widely used method for the
measurement of lung metastases in previous reports has been
the graphical method on semi-logarithmic paper (Collins et
al., 1956; Schwartz, 1961). In this study, a more convenient
and objective method based on linear regression is demon-
strated, which may be done with an ordinary desk-top com-
puter.
The reliability of measuremnent of tumour doubling times
from chest x-rays has previously been only briefly discussed
(Brenner et al., 1967). In this study each metastasis was
measured by two different investigators and the level of
agreement assessed.
Materials and methods
Between 1985 and 1990, 80 patients with lung metastases
from soft-tissue or skeletal sarcomas were treated by the
sarcoma group at the Department of Radiotherapy and
Oncology, University of Helsinki. Twenty-three of these had
bi-dimensionally measurable metastases in at least two
sequential chest x-rays taken at least 14 days apart. The
reason for exclusion was lack of follow-up in almost all
excluded case. Patients on chemotherapy were included when
at least one month had elapsed since the last chemotherapy
cycle. No patients received chemotherapy during the period
of measurement. The metastases were measured by two
independent investigators (MT and TW). Only metastases
considered measurable by both investigators were included in
the calculations. Metastases, which according to the
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measurements did not grow in size (nine metastases in five
patients with a median area of 1.3 cm2) were excluded, which
led to the exclusion of 2 patients from the study because
none of the measured metastases seemed to increase in size
during the follow-up period.
The final patient material consisted of 21 patients, and the
total number of measured metastases was 52.
The largest longitudinal diameter (dl) and the largest trans-
verse diameter perpendicular to this (d2) were measured from
chest x-rays by the two investigators. In the measurements
only PA (postero-anterior) views were utilised, since reliable
measurements from lateral chest views were impossible to
perform in a number of cases. In the calculations of cross-
section area an elliptic shape of the metastases with an area
of (n*dl*d2)/4 is postulated.
A regression analysis was performed on the logarithm of
the product of the two perpendicular diameters versus time.
A linear regression equation of the form y= ax+ b was
calculated for each metastasis, where y = ln(dl*d2),
ln = natural logarithm, dj = the longitudinal diameter,
d2= the transverse diameter, a = the slope of the regression
equation, x = the time from baseline, b = the constant term
of the regression equation. The volume doubling time ofeach
metastasis (T2) was calculated from the slope (a) of the
regression equation according to the formula T2 = 2ln2/3a.
The geometric mean of the estimates by the two investi-
gators was used unless otherwise indicated. In patients with
more than one metastasis the geometric mean of the doubling
times of individual metastases was used as the patient-specific
doubling time.
The statistical significance of the difference between inter-
and intrapatient variation of tumour doubling times was
studied with analysis of variance. The 95% range of agree-
ment between the doubling time measurement by the two
investigators was estimated from the standard deviation of
the quotient of the two estimates under the assumption of a
log-normal distribution (Brennan & Silman, 1992). The
statistical significance of investigator bias in the estimates of
the doubling time was tested with the one-sample t-test on
the logarithm of the quotient of the two investigators'
estimates.
The prognostic value of the doubling time for overall
survival tested in a Cox analysis with the BMDP computer
program (Dixon et al., 1988).
Results
The mean age of the patients was 47 years. Nine were
females. Seven patients had previously received cytotoxic
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Table I Clinical characteristics of the patients and estimated tumour doubling times
Sex and Number of
age previous CT Number of Number of Total measurement AT2*
Histology Grade Site regimens metastases measurements tine (months) T2 (days) (%)
M20 Chondrosarcoma 3 Pelvis 3 1 5 315 1172 -65
M21 Osteosarcoma 4 Tibia 0 1 3 35 50 -15
M27 Sarcoma NOS 4 Neck 1 6 5 77 39 -41
M29 Sarcoma NOS 4 Axilla 0 7 2 89 32 -40
M34 Sarcoma Ewing 4 Maxilla 1 1 4 27 28 15
F35 Leiomyosarcoma 4 Scapula 3 1 2 26 11 20
F36 Sarcoma Ewing 4 Buttock 0 1 3 39 16 -6
M37 Sarcoma NOS 4 Buttock 0 2 2 14 16 -22
F41 Sarcoma NOS 4 Upper arm 3 4 4 80 74 -17
M42 MFH 4 Thigh 0 3 3 20 9 0
F51 Schwannoma malignum 3 Retroperitoneum 0 1 2 36 29 3
F51 Sarcoma NOS 4 Axilla 0 1 2 232 54 -2
M54 Liposarcoma 4 Upper leg 0 2 2 84 35 -11
M55 Liposarcoma 3 Shoulder 0 1 3 91 75 -7
F56 Leiomyosarcoma 3 Uterus 1 5 4 55 37 15
M61 Sarcoma NOS 4 Maxilla 0 1 2 34 37 5
F63 Sarcoma NOS 4 Foot 0 1 3 43 26 21
M64 Sarcoma synoviale 3 Hip 1 2 7 231 60 2
M66 Sarcoma NOS 4 Groin 0 3 2 21 14 -7
F67 MFH 4 Calf 0 1 2 14 7 -25
F68 Leiomyosarcoma 2 Retroperitoneum 0 6 9 819 276 -6
*Discrepancy in T2 (A T2) estimated by two (MT and TW) independent investigators calculated as [(T2MT/T2TW) - 11*100. M = male;
F = female.
treatment. Patient characteristics, the number of measured
metastases, the number of measurement time points, the time
interval from the first to the last measurement and the cal-
culated doubling times of the metastases in the individual
patients is shown in Table I. The median metastasis doubling
time for the 21 patients was 34.9 days and the geometric
mean ofT2 was 36.9 days (range 7 to 1172 days). In a probit
plot of the logarithm of T2 the data points seemed to lie
along a straight line (r = 0.94) indicating that the distribution
was approximately log-normal. Under assumption of a log-
normal distribution with a geometric mean of 36.9 days the
estimated 95% range (tolerance interval) of doubling times
was 3.9 to 352 days.
Reproducibility ofthe measurements
The doubling times measured by the two investigators
showed were in good agreement in most cases. In a few
cases, however, there was a considerable discrepancy between
the estimates according to the measurements by the two
observers (Table I). The estimates of the first investigators
(MT) was in an average 16% lower than those of the second
(TW). This difference was statistically significant (P = 0.01).
The investigator obtaining the lower estimates of T2 also
obtained significantly smaller measurements of the sizes of
the metastases (mean difference 7% or 0.41 cm2,
P = 0.0001).
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Figure 1 Growth measurements of metastases in twelve patients with more than two measurements ofeach metastasis. The patient
identification code denotes sex (F = female, M = male) and age at primary diagnosis. T2 are given in days. The scale of the abscissa
(time) is linear and the scale of the ordinata (size) logarithmic.
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Figure 2 Correlation between the logarithm of T2 and log-
survival time from the detection of metastases.
The estimated 95% range for the quotient of the two T2
measurements of the 52 individual metastases was 0.318 to
2.22. Thus the discrepancy of two independent estimates of
T2 are expected to lie between 68% and + 122% in 95%
of cases. The estimated 95% range for the patient specific T2
calculated as the geometric mean of the doubling times of
multiple metastases for each patient was narrower, 53% to
+ 67%.
Variation in doubling times between different metastases in the
same patients compared to variation between patients
Eleven patients had more than one measurable metastasis.
The variance in T2 significantly (P
= 0.0001) larger between
the patients (mean square of natural logarithm of the doub-
ling time between patients 3.6) than within each patient
(mean square of In doubling time within patients 0.43)
Evidence of exponential growth in patients with three or more
measurements
Twenty-seven metastases in 12 patients were measurable
more than twice (Figure 1). Linear regression of the
logarithms of the sizes of these metastases yielded linear
correlations very close to unity in most cases (r
= 0.66 to
0.998, median 0.987).
Correlation between doubling time and survival
There was a positive correlation (r
= 0.55) between metastasis
doubling time and the survival time from the diagnosis of
metastatic disease (Figure 2). In a Cox proportional hazard
model, however, the tumour doubling time did not attain
statistical significance as a prognostic variable for survival
time (P
= 0.10O, no other factors included in the model).
Discussion
Charbit et at., reviewed the literature on the growth rate of
human tumours, and found a total of 87 published cases of
mesenchymal tumours (Charbit, et at., 1971). Since that only
a few additional series have been published on measurement
of T2 in metastases from sarcomas (Band & Kocandrle, 1975;
Chaninian, 1972; R66ser, et at., 1987). Most previous series
are small, the only s;tudy larger than the present onet isz the-
series of Breur et al. (Breur, 1966).
The sarcoma group at the University of Helsinki has been
treating bone sarcoma patients on a centralised fashion since
1981 and soft-tissue sarcomas since 1987. Approximately five
new cases of bone sarcomas and 50 new soft-tissue sarcomas
are seen yearly. After primary treatment the patients are
followed up with two to six months intervals and chest x-rays
are taken at each visit. This has provided a representative
patient material to study the growth characteristics of lung
metastases. Despite the relatively intense follow-up only
about one fourth of the patients with lung-metastases were
found to have measurable lesions not undergoing treatment
and visible in at least two chest x-rays.
In previous studies, the graphic method has been the most
commonly used (Brenner et al., 1967; Collins et al., 1956;
Rooser et al., 1987). This method has the drawback of being
prone to bias, since the straight lines adjoining the measure-
ment points are estimated by eye-sight. In our study a more
objective method based on linear regression analysis is used.
This method can be performed with commonly available
statistical computer programs. We are aware of only one
previous publication of this method in which, however, the
methodology is only briefly outlined (Mattson et al., 1980).
In the present study the size of the metastases were measured
only on PA chest views, since the measurement ofthe sagittal
diameter proved difficult in many cases. It can be shown by
elementary calculation that volume doubling time can be
calculated from cross-section areas without estimation of the
third diameter providing the shape of the tumour remains
constant.
In the review by Charbit et al. a median T2 of malignant
mesenchymal tumours of 37 days and a geometric mean of
41.4 days was observed in 87 patients (Charbit et al., 1971).
These figures agree very well with ours. As in previous
studies the distribution of T2 was approximately log-normal
(Charbit et al., 1971; Spratt, 1965; Spratt & Spratt, 1964).
The span of interpatient variation of T2 in this patient
material was almost 100-fold, and an estimated 95% range of
the same magnitude. The wide range of doubling times in
sarcomas is probably one of the factors responsible for the
large variation in the clinical behaviour of these tumours.
Like previous investigators (Brenner et al., 1967; Rooser et
al., 1987) we found that the variation in T2 between indivi-
dual patients was considerably larger than between different
metastases in the same patient. Statistical testing of this
difference showed it to be highly significant, providing formal
evidence for this previously reported finding.
There was a positive correlation between the logarithm of
T2 and the logarithm of survival time from detection of
metastases. The scatter around the regression line was, how-
ever, considerable, and the coefficient of determination (r2)
was only 0.30. Thus differences in T2 explained only one
third of the variation of the survival times from detection of
metastatic disease. T2 has previously been found to correlate
well with the prognosis in both sarcomas (Joseph et al., 1971)
and lung tumours of other histology (Mattson & Holsti,
1980) and in sarcoma patients after resection of lung meta-
stases (Spratt & Spratt, 1964). When tested as a prognostic
factor for survival with a conventional Cox model T2 did,
however, not reach statistical significance in this study, pos-
sibly because of the small sample size. Even if metastasis
doubling time may be a valuable prognostic factor for out-
come in metastatic lung disease its practical use is diminished
by the fact that only a minority of patients (in this study one
fourth) have metastases that are reliably measurable.
In animal studies it has been shown that many tumours do
not grow in a constant exponential fashion, and that T2 is
retarded when the tumour grows in size; this is referred to as
Gompertzian growth (Laird, 1964; Laird, 1965). In human
tumours, however, no visible evidence of Gompertzian
growth of lung metastases has been found by previous inves-
tigators (Brenner et al., 1967; Breur, 1966; Rooser et al.,
1987; Schwartz, 1961). Twelve patients in this study had
measurements more than twice. No evidence of Gompertzian
growth was found in these patients; the growth of most
metastases seemed to be well described by an exponential
function during the whole observation period, seen as a high
linear correlation of the logarithm of metastatic area with
time. The reason for the failure to detect Gompertzian
growth in human tumours is unclear, but may partly be a
reflection of the limited potential follow-up times in human
tumours.
Little data are available on the reproducibility ofGROWTH RATE OF SARCOMA LUNG METASTASES 417
measurements of growth rate of neoplastic lung lesions.
Brenner has estimated the error of measurements of T2 of
lung metastases to be 11% or less, assuming a follow-up time
twice the tumour doubling time and measurements from six
different radiographs (Brenner et al., 1967). In a human
patient material the need for early treatment precludes such a
long follow-up in most cases. In this study measurements
were performed by two independent investigators. The dis-
agreement between the two estimates of T2 of individual
metastases was surprisingly large. The repeatability of the
patient specific T2 was better. Most of the disagreement
originated from a few patients with small poorly visible
metastases. Moreover, the four- to seven-fold range of
disagreement in estimates is still small compared to the 100-
fold variation of T2 between different patients. Interestingly
one of the two investigators seemed to obtain significantly
lower values of T2 than the other, even if the systematic bias
was negligibly small. This, however, underscores the necessity
of having all measurements done by the same investigator in
repeated measurements.
The authors wish to thank professor Marten Brenner for valuable
comments on the mathematical methodology.
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